Healthcare Reform Implications for the Pharmaceutical Industry Highlighted in New Book, Pharmaplasia™, Published by PharmaReform.com author, Mike Wokasch
“… Pharmaplasia is important reading for anyone with a vested interest in the pharmaceutical industry (especially those who work in it).”
(Four of Five Stars)
Unlike other books written about the pharmaceutical industry, Mike Wokasch, a 30 year industry veteran, delves into the causes of the industry’s current state of dysfunction. He provides practical solutions for a prosperous future, even in light of the increasing regulatory constraints, restrictions on marketing and sales, and the demands of an increasingly cost conscious market with its own challenges imposed by healthcare reform.
The author provides an insider’s perspective with unique insights into the unintended consequences of the industry’s rapid growth and explores why some Big Pharma companies may be too big for the complexities of the science, the business, and the market. Much like his blog PharmaReform.com, this 180 page book is not an exposé but rather a hard hitting discussion of how the industry’s mistakes and poor decisions have led to serious questions about its outdated business model, its long-term commercial viability, and the imbalance between corporate priorities for “profits and patients” that have driven product sales but often put patient health and safety at risk.
Pharmaplasia™, which is available in hard and soft cover at www.Pharmaplasia.com, addresses important management, organizational, functional, and philosophical questions such as:
- How will Healthcare Reform affect the pharmaceutical industry?
- What do pharmaceutical companies need to do to better align with the expectations of the market and to adapt to Healthcare Reform?
- What factors, actions, and decisions led to the current state of industry dysfunction?
- Why can’t $65 billion in annual R & D spending produce more innovative products?
- What did organizational growth do to pharmaceutical companies and the industry?
- Is the role of the pharmaceutical sales representative obsolete?
- What do pharmaceutical companies need to do to reestablish trust and credibility in the market?
- What should pharmaceutical executives focus on as they reconfigure their business models?
Industry executives and employees will relate to the historical insider perspective but more importantly, take away practical recommendations for increasing R & D productivity, preserving profitability in the face of healthcare reform, and reestablishing public trust and credibility.
Pharmaceutical industry service providers and vendors will better understand their customers and comprehend the transformative challenges the industry faces; ultimately they will be in a better position to align their products and services to the address the changing needs of the industry.
Healthcare providers will relate to how the industry needs to evolve, appreciate the need for and value of “conflict of interest-free” relationships with the industry, and gain further understanding of the important role they play in ensuring that their patients receive the best available treatment options.
Patients and the general public will enjoy the insider perspective about Big Pharma while learning what they should be able to expect from an industry we all depend upon for innovative new drug treatments that can relieve pain and suffering and save lives.
Preview Table of Contents
Preview Chapter 1
Go to www.Pharmaplasia.com